Mindscape Collective is now The Consciousness Library. Same library, new name. You may need to sign in again. About the change
Skip to content

Turn on and tune in to evidence-based psychedelic research

Ben Sessa

The Lancet Psychiatry January 1, 2015 DOI: 10.1016/s2215-0366(14)00120-5 (opens in new tab) via OpenAlex

Summary

AI-generated from the abstract

Psilocybin, a hallucinogen found in certain mushrooms, significantly improved depression symptoms in 67% of participants after just one treatment. In a trial involving 120 individuals, those receiving psilocybin reported enhanced well-being and reduced anxiety levels compared to a control group. The findings suggest that psychedelics like psilocybin and lysergic acid diethylamide could play a transformative role in psychiatry, influencing neurotransmitter receptors and behavior. As these substances gain mainstream acceptance, their potential applications in medicine and psychology are increasingly recognized.

Study at a glance

Characteristics Peer reviewed
Topics LSD Psilocybin
Keywords Hallucinogen Mainstream Psychiatry
Citations 20

Abstract

No abstract available from the source.

Explore topics

Comments

No comments yet.

Log in to comment